Dublin, April 25, 2018 -- The "The Global Influenza Market" report has been added to ResearchAndMarkets.com's offering.
This report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is global, with emphasis on U.S. and European data.
The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
Report Includes:
- 25 data tables and 77 additional tables
- An overview of the global influenza market
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Identification of segments with high growth potential and their future applications
- Explanation of major drivers and regional dynamics of the market and current trends within the industry
- Detailed profiles of major vendors in the market, including Alere Inc., MedImmune, LLC, Cepheid Inc., GlaxoSmithKline plc and Qiagen N.V.
Key Topics Covered:
1 Introduction
- Influenza Overview
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Related Reports
2 Summary and Highlights
- The Influenza Market: Summary of Major Markets
3 Industry Overview and Background
- Overview
- History of the Market
- Epidemics and Pandemics in History
- Virus Mutations
- Influenza Types
- WHO and CDC Influenza Response
- World Health Organization
- Centers for Disease Control and Prevention
- U.S. Viral Surveillance
- FDA's Vaccine and Related Biological Products Advisory Committee and Vaccine Composition
- Vaccine Recommendations
- Vaccine Effectiveness
- Universal Vaccine
- Population Demographics and Influenza Incidence/Mortality
- Global Demographics
- Global Life Expectancy
- Influenza Incidence and Mortality
- The 2017-2018 Influenza Season (Through January 2018)
4 Global Influenza Vaccine Market
- Overview
- Current Vaccines
- The Global Influenza Vaccine Market
- Seasonal versus Pandemic Sales
- Regional Market Summary
- The U.S. Influenza Vaccine Market
- History of Vaccine Manufacturer Participation in the United States
- The European Influenza Vaccine Market
- Global Competitor Analysis
- Influenza Vaccine Developments
- Clinical Trials
5 Global Influenza Therapeutics Market
- Overview
- Current Therapies
- Generic Availability
- The Global Influenza Therapeutics Market
- Seasonal versus Pandemic Sales
- Regional Market Summary
- The U.S. Influenza Therapeutics Market
- The European Influenza Therapeutics Market
- Global Competitor Analysis
- Influenza Treatment Developments
- Clinical Trials
6 Global Influenza Diagnostic Market
- Overview
- Test Descriptions
- Product Descriptions
- Laboratory Services
- The Global Influenza Diagnostic Market
- Regional Market Summary
- Global Competitor Analysis
7 Influenza Pandemic Impact
- Epidemic/Pandemic Threat
- H1N1 Outbreak 2009 (Swine Flu)
- Rapid Diagnostics
- Pandemic Testing
- Seasonal Influenza Tests
- Avian Flu
- Avian Flu Surveillance
- The WHO and Containment for Pandemic Influenza
- International Influenza Vaccine Stockpile Orders
- Pre-Pandemic Vaccination
- Biomedical Advanced Research and Development Authority (BARDA)
- Antiviral Resistance
- Recreated Viruses
- Immaterialized Market Risk
- Media Coverage and Vaccinations
- Pandemic Preparedness Plans
- Infrared Sensors and Thermal Imagers
- The United States
- Japan
- China
- Brazil
- United Kingdom
8 Patent Review/ New Developments
- Overview
- Influenza Patent Review by Year
- Influenza Patent Review by Country
- Influenza Patent Review by Assignee
- Massachusetts Institute of Technology (MIT)
- Seqirus U.K. Limited
- Academia Sinica
- Celltrion Inc.
- Icahn School of Medicine at Mount Sinai
- Shionogi & Co. Ltd.
- Vertex Pharmaceuticals Inc.
- Xiamen University
9 Analysis of Market Opportunities
- Overview of Influenza Market Trends
- Total Market Analysis
- Regional Market Summary
10 Company Profiles
- Alere Inc.
- Medimmune/Astrazeneca
- Medimmune Inc.
- Becton Dickinson And Company
- Cepheid
- Daiichi Sankyo
- Glaxosmithkline Plc
- Hologic Inc
- Luminex Corp.
- Mitsubishi Tanabe Pharma Corp.
- Mylan N.V.
- Orasure Technologies
- Qiagen N.V.
- Quidel Corp.
- Roche
- Sanofi/Sanofi Pasteur
- Sekisui Diagnostics Llc
- Seqirus
For more information about this report visit https://www.researchandmarkets.com/research/9xddcp/global_influenza?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs


Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal
How Marco Pharma International Preserves German Homeopathic Traditions in America
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 



